PMID- 24675233
OWN - NLM
STAT- MEDLINE
DCOM- 20141118
LR  - 20220317
IS  - 1531-703X (Electronic)
IS  - 1040-8746 (Print)
IS  - 1040-8746 (Linking)
VI  - 26
IP  - 3
DP  - 2014 May
TI  - Renal cell carcinoma: molecular biology and targeted therapy.
PG  - 321-7
LID - 10.1097/CCO.0000000000000069 [doi]
AB  - PURPOSE OF REVIEW: Renal cell carcinoma (RCC) continues to be the subject of 
      vigorous clinical and translational investigation. Advances in systemic targeted 
      therapies, new molecular pathways and immunotherapy approaches will be discussed. 
      RECENT FINDINGS: Agents targeting the vascular endothelial growth factor (VEGF) 
      and/or the mammalian target of rapamycin (mTOR) pathways continue to be the 
      mainstay for treating metastatic RCC (mRCC). Although enhanced target specificity 
      has improved the toxicity profile associated with newer VEGF-pathway antagonists, 
      durable complete responses remain the exception. Identification of novel 
      pathways/agents, as well as the optimal sequencing and combination of existing 
      targeted agents, remain areas of active study. In addition, emerging data from 
      early clinical trials have reinvigorated interest in immunomodulatory agents. 
      SUMMARY: The therapeutic armamentarium available to genitourinary oncologists 
      continues to grow, but much work remains to be done to fully realize the 
      potential of pathway-specific targeted strategies and immune-based approaches for 
      mRCC.
FAU - Su, Daniel
AU  - Su D
AD  - aUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      National Institutes of Health, Bethesda, Maryland bSection of Urologic Oncology, 
      Rutgers Cancer Institute of New Jersey and Robert Wood Johnson Medical School, 
      New Brunswick, New Jersey, USA.
FAU - Stamatakis, Lambros
AU  - Stamatakis L
FAU - Singer, Eric A
AU  - Singer EA
FAU - Srinivasan, Ramaprasad
AU  - Srinivasan R
LA  - eng
GR  - P30 CA072720/CA/NCI NIH HHS/United States
GR  - Z99 CA999999/Intramural NIH HHS/United States
GR  - P30CA072720/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Review
PL  - United States
TA  - Curr Opin Oncol
JT  - Current opinion in oncology
JID - 9007265
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Renal Cell/genetics/*therapy
MH  - Humans
MH  - Immunotherapy/methods
MH  - Kidney Neoplasms/*drug therapy/genetics
MH  - Molecular Biology
MH  - Molecular Targeted Therapy/*methods
PMC - PMC4232438
MID - NIHMS637948
COIS- Conflicts of interest The authors report no conflicts of interest.
EDAT- 2014/03/29 06:00
MHDA- 2014/11/19 06:00
PMCR- 2015/05/01
CRDT- 2014/03/29 06:00
PHST- 2014/03/29 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2014/11/19 06:00 [medline]
PHST- 2015/05/01 00:00 [pmc-release]
AID - 10.1097/CCO.0000000000000069 [doi]
PST - ppublish
SO  - Curr Opin Oncol. 2014 May;26(3):321-7. doi: 10.1097/CCO.0000000000000069.